Cargando…
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer
Improvements in median overall survival in the advanced oesophagogastric (OG) setting have plateaued, underlining the need for improved therapeutic approaches in this patient population. Immunotherapeutics are inducing unexpected durable responses in an expanding list of advanced disease indications...
Autores principales: | Flynn, Michael, Young, Kate, Cunningham, David, Starling, Naureen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048671/ https://www.ncbi.nlm.nih.gov/pubmed/30034550 http://dx.doi.org/10.1177/1758835918786228 |
Ejemplares similares
-
Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies
por: Butters, Oliver, et al.
Publicado: (2019) -
Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study
por: Moorcraft, Sing Yu, et al.
Publicado: (2016) -
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
por: Rao, S, et al.
Publicado: (2008) -
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
por: Young, Kate, et al.
Publicado: (2018) -
Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2019)